hsa‑miR‑17‑5p: A Possible Predictor of Ombitasvir/Paritaprevir/ Ritonavir+Dasabuvir±Ribavirin Therapy Efcacy in Hepatitis C Infection
Zehra Öksüz | Enver Üçbilek | Mehmet Sami Serin | Serkan Yaraş | Gülhan Örekici | Temel Orhan Sezgin
Although persistent sustained viral response rates are increased in hepatitis C infection following administration of direct acting antiviral (DAA) agents, the pre-use predictive parameters of these antivirals and the clinical progression in patients post-treatment remain unknown. To obtain data pertaining to the predictive parameters prior to the use of ombitavir/paritaprevir/ritonavir+dasabuvir and the clinical progression in patients following antiviral treatment. The expression profles of miR-223-3p, miR-17-5p, miR-24-3p, and TLR2 − 196 to − 174 del/ins polymorphisms from the blood/serum of 34 hepatitis C virus (HCV)-infected patients pre- and post-ombitavir/paritaprevir/ritonavir+dasabuvir treatment were determined by RT-qPCR. The expression levels of miR-17-5p (P0.05); neverthe...
Harnessing Knowledge on Very Important Pharmacogenes CYP2C9 and CYP2C19 Variation for Precision Medicine in Resource-Limited Global Conflict Zones
Barlas, İbrahim Ömer | Sezgin, Orhan
Pharmacogenomics harnesses the utility of a patient’s genome (n = 1) in decisions on which therapeutic drugs and in what amounts should be administered. Often, patients with shared ancestry present with comparable genetic profiles that predict drug response. However, populations are not static, thus, often, population mobility through migration, especially enmasse as is seen for refugees, changes the pharmacogenetic profiles of resultant populations and therefore observed responses to commonly used therapeutic drugs. For example, in the aftermath of the Syrian civil war since 2011, millions have fled their homes to neighboring countries in the Middle East. The growing permanence of refugees and mass migrations is a call to shift our focus in the life sciences community from old models of p...